Establishing targets for advanced HIV disease: A call to action.
TB-LAM
advanced HIV disease
cryptococcal antigen
targets
tuberculosis
Journal
Southern African journal of HIV medicine
ISSN: 2078-6751
Titre abrégé: South Afr J HIV Med
Pays: South Africa
ID NLM: 100965417
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
05
2021
accepted:
27
06
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
The World Health Organization (WHO) has published a guideline for the management of individuals with advanced HIV disease (AHD) to reduce HIV-related deaths. The guideline consists of a package of recommendations including interventions to prevent, diagnose and treat common opportunistic infections, including tuberculosis (TB), cryptococcosis and severe bacterial infections, along with rapid initiation of antiretroviral treatment and enhanced adherence support. Currently no clear targets exist for these key interventions. Emerging programmatic data from Uganda, Tanzania and Nigeria suggest that an estimated 80% of eligible people continue to miss the recommended cryptococcal or TB testing, highlighting the remaining challenges to the effective implementation of WHO-recommended AHD packages of care in real-world resource-limited settings. The absence of mortality indicators for the leading causes of HIV-related deaths, because of the lack of mechanisms to ascertain cause of death, has had a negative impact on establishing interventions to reduce mortality. We suggest that setting 95-95-95 targets for CD4 testing, cryptococcal antigen and TB testing, and treatment that are aligned to the WHO AHD package of care would be a step in the right direction to achieving the greater goal of the WHO End TB strategy and the proposed new strategy to end cryptococcal meningitis deaths. However, these targets will only be achieved if there is healthcare worker training, expanded access to bedside point-of-care diagnostics for hospitalised patients and those in outpatient care who meet the criteria for AHD, and health systems strengthening to minimise delays in initiating the WHO-recommended therapies for TB and cryptococcal disease.
Identifiants
pubmed: 34522428
doi: 10.4102/sajhivmed.v22i1.1266
pii: HIVMED-22-1266
pmc: PMC8424734
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1266Subventions
Organisme : Medical Research Council
ID : MC_PC_MR/P006922/1
Pays : United Kingdom
Informations de copyright
© 2021. The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Références
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S111-S117
pubmed: 29514238
Lancet Infect Dis. 2021 Sep;21(9):e259-e271
pubmed: 33872594
J Sex Transm Dis. 2017;2017:7075601
pubmed: 28702270
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):427-430
pubmed: 33764960
Medicine (Baltimore). 2018 Aug;97(31):e11722
pubmed: 30075580
PLoS One. 2019 Jan 10;14(1):e0210105
pubmed: 30629619
J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e37-e42
pubmed: 26926942
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S118-S125
pubmed: 29514233
HIV Med. 2021 Jan;22(1):1-10
pubmed: 32876378
Lancet Glob Health. 2016 Nov;4(11):e816-e826
pubmed: 27720689
Lancet Infect Dis. 2019 Aug;19(8):843-851
pubmed: 31345462
Int J Infect Dis. 2021 Mar 11;:
pubmed: 33716195
Clin Infect Dis. 2019 Aug 1;69(4):588-595
pubmed: 30863852
Lancet Infect Dis. 2017 Aug;17(8):873-881
pubmed: 28483415
Open Forum Infect Dis. 2019 Sep 29;6(10):ofz419
pubmed: 31660375